{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01205022: Phase 1 Interventional Completed Recurrent Colon Cancer
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02129075: Phase 2 Interventional Completed Cutaneous Melanoma
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03526835: Phase 1/Phase 2 Interventional Recruiting Advanced/Metastatic Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ozuriftamab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03476252: Not Applicable Interventional Unknown status Myocardial Infarction
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:volrustomig [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:nivisnebart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sovipostobart beta [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ivonescimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:iparomlimab [INN]
Source URL:
Class:
PROTEIN
